Scientific Opinion on the substantiation of health claims related to galacto-oligosaccharides (GOS) and reduction of gastro-intestinal discomfort (ID 763) and decreasing potentially pathogenic microorganisms (ID 765) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

被引：1

作者：

Agostoni, Carlo ^{[1
]}

Bresson, Jean-Louis ^{[1
]}

Fairweather-Tait, Susan ^{[1
]}

Flynn, Albert ^{[1
]}

Golly, Ines ^{[1
]}

Korhonen, Hannu ^{[1
]}

Lagiou, Pagona ^{[1
]}

Lovik, Martinus ^{[1
]}

Marchelli, Rosangela ^{[1
]}

Martin, Ambroise ^{[1
]}

Moseley, Bevan ^{[1
]}

Neuhaeuser-Berthold, Monika ^{[1
]}

Przyrembel, Hildegard ^{[1
]}

Salminen, Seppo ^{[1
]}

Sanz, Yolanda ^{[1
]}

Strain, Sean ^{[1
]}

Strobel, Stephan ^{[1
]}

Tetens, Inge ^{[1
]}

Tome, Daniel ^{[1
]}

van Loveren, Hendrik ^{[1
]}

Verhagen, Hans ^{[1
]}

机构：

[1] EFSA, Parma, Italy

来源：

EFSA JOURNAL | 2011年 / 9卷 / 04期

关键词：

Galacto-oligosaccharides; gastro-intestinal discomfort; pathogenic gastro-intestinal microorganisms; health claims;

D O I：

10.2903/j.efsa.2011.2060

中图分类号：

TS2 [食品工业];

学科分类号：

0832 ;

摘要：

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims in relation to galacto-oligosaccharides and reduction of gastro-intestinal discomfort and decreasing potentially pathogenic microorganisms. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders. The food constituent that is the subject of the health claims is galacto-oligosaccharides (GOS). The Panel considers that galacto-oligosaccharides (GOS) are sufficiently characterised in relation to the claimed effects. Reduction of gastro-intestinal discomfort The claimed effect is "maintains a healthy normal digestive system". The target population is assumed to be the general population. In the context of the proposed wording, the Panel assumes that the claimed effect refers to a reduction of gastro-intestinal discomfort. The Panel considers that a reduction of gastro-intestinal discomfort is a beneficial physiological effect. No references have been provided from which conclusions could be drawn for the scientific substantiation of the claimed effect. On the basis of the data presented, the Panel concludes that a cause and effect relationship has not been established between the consumption of galacto-oligosaccharides (GOS) and a reduction of gastro-intestinal discomfort. Decreasing potentially pathogenic gastro-intestinal microorganisms The claimed effect is "prebiotic/bifidogenic". The target population is assumed to be the general population. In the context of the proposed wordings, the Panel assumes that the claimed effect refers to increasing numbers of bacteria which are considered to be "beneficial". The Panel considers that the evidence provided does not establish that increasing numbers of groups of gastro-intestinal microorganisms is a beneficial physiological effect. The Panel considers that the claimed effect in the context of decreasing potentially pathogenic gastro-intestinal microorganisms might be a beneficial physiological effect. No human studies have been provided from which conclusions could be drawn for the scientific substantiation of the claimed effect. On the basis of the data presented, the Panel concludes that a cause and effect relationship has not been established between the consumption of galacto-oligosaccharides (GOS) and decreasing potentially pathogenic gastro-intestinal microorganisms.

引用

页数：15

共 10 条

[1]

Alles MS, 1999, AM J CLIN NUTR, V69, P980

[2] The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans:: a double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study [J].